LIPO

Lipella Pharmaceuticals, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website lipella.com
Employees(FY) 5
ISIN US53630L2097

Performance

-18.31%

-39.08%

-26.77%

-59.89%

-70.47%

YTD

-74.25%

Profile

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.

Advanced Technical Analysis

Technical Analysis of LIPO 2024-11-20

The stock indicators reflect a predominantly bearish sentiment, with a Moving Average Score of 10 indicating strong downward momentum, an Oscillators Score of 40 suggesting a neutral stance, and a Technical Score of 25 reinforcing the overall bearish outlook. This combination signals caution for potential investors as the market shows limited bu...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of LIPO

Stock Rank

Recent News & Updates

2024-11-11 16:30
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform(Globenewswire)
2024-11-01 04:30
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split(Globenewswire)
2024-10-28 20:30
Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference(Globenewswire)
2024-10-14 17:00
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform(Globenewswire)
2024-10-08 22:47
Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit(Globenewswire)
2024-09-24 20:30
PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month(Globenewswire)
2024-09-23 20:00
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus(Globenewswire)
2024-08-26 20:00
Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York(Globenewswire)
2024-08-21 17:00
Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research(Globenewswire)
2024-08-20 17:00
Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference(Globenewswire)
2024-08-11 18:52
Lipella doses first two subjects in Phase IIa oral lichen planus treatment trial(Yahoo Finance)
2024-08-11 17:00
Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial(Globenewswire)
2024-08-01 04:05
Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules(Globenewswire)
2024-07-31 20:00
Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules(Globenewswire)
2024-07-28 17:00
Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients(Globenewswire)
2024-05-30 20:00
Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus(Globenewswire)
2024-05-29 00:53
LIPO Stock Earnings: Lipella Pharmaceuticals Reported Results for Q1 2024(Investorplace)
2024-05-28 20:00
Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting(Globenewswire)
2024-05-24 01:53
LIPO Stock Earnings: Lipella Pharmaceuticals Reported Results for Q4 2023(Investorplace)
2024-05-20 20:00
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b(Globenewswire)
2024-04-16 20:00
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise(Globenewswire)
2024-04-04 20:00
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024(Globenewswire)
2024-04-02 20:00
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis(Globenewswire)
2024-03-07 02:23
PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease(Yahoo Finance)
2024-03-04 19:00
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline(Yahoo Finance)
2024-02-19 19:00
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference(Globenewswire)
2023-12-19 19:00
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished(Globenewswire)
2023-11-12 07:20
Lipella Pharmaceuticals gets ODD for LP-310 to treat GvHD(Pharmaceutical-business-review)
2023-11-09 19:00
FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease(Prnewswire)
2023-10-25 04:05
Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules(Yahoo Finance)

Page 1 of 2

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.